GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (FRA:6LP) » Definitions » Additional Paid-In Capital

Bolt Biotherapeutics (FRA:6LP) Additional Paid-In Capital : €440.95 Mil(As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics Additional Paid-In Capital?


Bolt Biotherapeutics's quarterly additional paid-in capital declined from Sep. 2023 (€444.90 Mil) to Dec. 2023 (€437.40 Mil) but then increased from Dec. 2023 (€437.40 Mil) to Mar. 2024 (€440.95 Mil).

Bolt Biotherapeutics's annual additional paid-in capital increased from Dec. 2021 (€404.83 Mil) to Dec. 2022 (€441.33 Mil) but then declined from Dec. 2022 (€441.33 Mil) to Dec. 2023 (€437.40 Mil).


Bolt Biotherapeutics Additional Paid-In Capital Historical Data

The historical data trend for Bolt Biotherapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics Additional Paid-In Capital Chart

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 1.64 2.84 404.83 441.33 437.40

Bolt Biotherapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 438.97 436.10 444.90 437.40 440.95

Bolt Biotherapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Bolt Biotherapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Bolt Biotherapeutics (FRA:6LP) Business Description

Traded in Other Exchanges
Address
900 Chesapeake Drive, Redwood, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.

Bolt Biotherapeutics (FRA:6LP) Headlines

No Headlines